The board of directors of Juno has determined that the offer is fair, advisable and in the best interest of Juno and its stockholders and recommends that the stockholders of Juno tender their shares.
The tender offer is scheduled to expire at
Complete terms and conditions of the tender offer can be found in the
Offer to Purchase, Letter of Transmittal and other related materials
that will be filed by
Copies of the Offer to Purchase, Letter of Transmittal and other related
materials are available free of charge by contacting Morrow Sodali, the
information agent for the tender offer, toll-free at 800-662-5200 (or at
1-203-658-9400 collect if you are located outside the
About Celgene
About Juno
Additional Information about the Transaction and Where to Find It
This news release and the description contained herein is for
informational purposes only and is not an offer to buy or the
solicitation of an offer to sell any shares of Juno. Celgene and its
subsidiary,
Forward-Looking Statements
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. Celgene and Juno undertake no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and uncertainties,
most of which are difficult to predict and are generally beyond the
control of either company, including the following: (a) the occurrence
of any event, change or other circumstance that could give rise to the
termination of the merger agreement; (b) the inability to complete the
transaction due to the failure to satisfy conditions to the transaction;
(c) the risk that the proposed transaction disrupts current plans and
operations; (d) difficulties or unanticipated expenses in connection
with integrating Juno into Celgene; (e) the risk that the acquisition
does not perform as planned; and (f) potential difficulties in employee
retention following the closing of the transaction. Actual results or
outcomes may differ materially from those implied by the forward-looking
statements as a result of the impact of a number of factors, many of
which are discussed in more detail in the public reports of each company
filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20180202005228/en/
Celgene:
Investors:
908-673-9628
investors@celgene.com
or
Media:
908-673-2275
media@celgene.com
Source:
News Provided by Acquire Media